Theravance Biopharma to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
A live broadcast will be available by visiting the Investor Relations section of
Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S.,
In addition, we have an economic interest in future payments that may be made by
For more information, please visit www.theravance.com.
THERAVANCE®, the Cross/Star logo, and VIBATIV® are registered trademarks of the
Head of Investor Relations
View original content with multimedia:http://www.prnewswire.com/news-releases/theravance-biopharma-to-present-at-the-morgan-stanley-15th-annual-global-healthcare-conference-300513209.html